UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 10, 2005
(Exact name of registrant as specified in its charter)
|
MASSACHUSETTS |
|
000-19319 |
|
04-3039129 |
|
(State or other jurisdiction of |
|
(Commission File Number) |
|
(IRS Employer Identification |
130 Waverly Street
Cambridge, Massachusetts 02139
(Address of principal executive offices) (Zip Code)
(617) 444-6100
Registrant’s telephone number, including area code:
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 2.02. Results of Operations and Financial Condition.
On January 10, 2005, Vertex Pharmaceuticals Incorporated (the “Company”) issued a press release announcing its intention to review its 2004 achievements and to describe its 2005 product development goals and anticipated 2005 financial performance at JPMorgan’s 23rd Annual Healthcare Conference in San Francisco. Joshua Boger, Ph.D., Chairman and CEO of the Company will present this update. A live webcast of the presentation will be available on the Company’s website, www.vrtx.com, at 4:30 p.m. EST on January 10, 2005. An archived webcast of the presentation will be available on the Company’s website through January 24, 2005.
A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 7.01. Regulation FD Disclosure.
See Item 2.02.
Item 9.01. Financial Statements and Exhibits.
(c) Exhibits
|
Exhibit |
|
Description of Document |
|
|
|
|
|
|
|
99.1 |
|
Press Release of Vertex Pharmaceuticals Incorporated, dated January 10, 2005, titled “Vertex Pharmaceuticals Updates Business Progress and Announces 2005 Product Development Goals at 23rd Annual JPMorgan Healthcare Conference”. |
|
In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
2
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
VERTEX PHARMACEUTICALS |
|
|
(Registrant) |
|
|
|
|
Date: January 10, 2005 |
/s/ Kenneth S. Boger |
|
|
Kenneth S. Boger |
|
|
Senior Vice President and General Counsel |
3